SCHEMBL3673483

SCHEMBL3673483

Clc1ccc(NC2CCCCC2)c(Br)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT5B Q4FZB7 2/20 0.50
KMT5C Q86Y97 2/20 0.50
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
MAPT P10636 2/20 0.47
NPC1 O15118 2/20 0.47
CYP1A2 P05177 1/20 0.47
MAPK1 P28482 1/20 0.47
CYP2C19 P33261 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RIPK1 Q13546 1/20 0.46
RAB9A P51151 2/20 0.44
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
IDO1 P14902 1/20 0.41
CNR1 P21554 1/20 0.40
WNK1 Q9H4A3 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
CA1 P00915 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16334269 0.98 KMT5B (0.51) KMT5BKMT5CMEN1KMT2AMAPT
SCHEMBL17630208 0.91 NPC1 (0.43) KMT5BKMT5CMEN1KMT2AMAPT
SCHEMBL3786467 0.84 KMT5B (0.54) KMT5BKMT5CMEN1KMT2AMAPT
SCHEMBL31196551 0.82 NPC1 (0.60) KMT5BKMT5CMEN1KMT2AMAPT
SCHEMBL7794566 0.80 RAB9A (0.59) KMT5BKMT5CMEN1KMT2AMAPT
SCHEMBL3674808 0.79 NPC1 (0.51) KMT2AMAPTNPC1RAB9AKDM4E
SCHEMBL3792292 0.79 KDM4E (0.59) KMT5BKMT5CMEN1KMT2AMAPT
SCHEMBL3681747 0.79 NPC1 (0.47) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL3679064 0.78 MAPT (0.41) MEN1KMT2AMAPTKDM4EGAA
Methylamine SCHEMBL28000459 0.77 MAPT (0.44) MEN1KMT2AMAPTNPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966225-B1 TRANSITION METAL COMPLEXES AND PREPARATION METHODS THEREOF LG CHEMICAL LTD (KR) 2013-12-25 EP disclosed
EP-1966223-B1 CATALYST COMPOSITION COMPRISING GROUP 4 TRANSITION METAL COMPLEXES AND METHOD FOR PREPARING POLYOLEFINS USING THE SAME LG CHEMICAL LTD (KR) 2013-08-14 EP disclosed
US-7807762-B2 Catalyst composition comprising Group 4 transition metal complexes and method for preparing polyolefins using the same LG CHEM, LTD. (KR) 2010-10-05 US disclosed
US-7678933-B2 Transition metal complexes and preparation methods thereof LG CHEM, LTD. (KR) 2010-03-16 US disclosed
US-20090030221-A1 Transition Metal Complexes and Preparation Methods Thereof LG CHEM, LTD (KR) 2009-01-29 US disclosed
US-20090005525-A1 Catalyst Composition Comprising Group 4 Transition Metal Complexes and Method for Preparing Polyolefins Using the Same LG CHEM , LTD. (KR) 2009-01-01 US disclosed
EP-1966223-A1 CATALYST COMPOSITION COMPRISING GROUP 4 TRANSITION METAL COMPLEXES AND METHOD FOR PREPARING POLYOLEFINS USING THE SAME LG Chem. Ltd. (KR) 2008-09-10 EP disclosed
EP-1966225-A1 TRANSITION METAL COMPLEXES AND PREPARATION METHODS THEREOF LG Chem, Ltd. (KR) 2008-09-10 EP disclosed
WO-2007078134-A1 TRANSITION METAL COMPLEXES AND PREPARATION METHODS THEREOF LG CHEM. LTD. (KR) 2007-07-12 WO disclosed
WO-2007078133-A1 CATALYST COMPOSITION COMPRISING GROUP 4 TRANSITION METAL COMPLEXES AND METHOD FOR PREPARING POLYOLEFINS USING THE SAME LG CHEM. LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030221-A1 Transition Metal Complexes and Preparation Methods Thereof PICALM, TEC, PPIP5K2 KMT5B 92/4885KMT5C 86/4885MEN1 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.